Boston Scientific’s BSX Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. This segment reflects the company’s long-term commitment to gain leadership through innovation and targeted acquisitions, along with strategies to sustain and accelerate growth across neuromodulation therapies.
Neuromodulation delivered a strong quarter, with organic sales increasing 15% and the comprehensive portfolio posting low double-digit growth. The pain management business grew in the mid-teens, supported partially by a strong contribution from the acquisition of Nalu (completed in late January 2026).
Intracept continued to gain momentum, driven by compelling five-year clinical data demonstrating its long-term efficacy and cost-effectiveness in treating chronic low back pain. Within DBS, adoption of the Cartesia X leads remained strong, while the Illumina 3D programming algorithm saw accelerating uptake across the United States.
Boston Scientific continues to invest in neuromodulation platforms while strengthening its commercial capabilities. The Neuromodulation segment showed improvement, supported by organic contributions from acquisitions such as Relievant and Axonics in 2025. Management expects the Neuromodulation business to grow faster than the broader market over time.
Updates on BSX’s Neuromodulation Competitors
NeuroPace NPCE delivered a strong neuromodulation business performance in fourth-quarter 2025, driven by continued adoption of its responsive neurostimulation (RNS) platform for drug-resistant epilepsy. The company also accelerated development of AI-enabled neuromodulation tools like Seizure ID — an AI-driven platform designed to analyze intracranial EEG recordings, identify seizure activity, and improve physician workflow efficiency.
Medtronic's MDT Neuromodulation business reported 4% growth in the fiscal third quarter, with the ongoing rollout of its Inceptiv spinal cord stimulation (SCS) system and BrainSense adaptive DBS (aDBS) platforms. Inceptiv spinal cord stimulation system is the smallest and thinnest closed-loop SCS device available and offers best-in-class MRI compatibility. With neuromodulation systems’ adoption expanding across major geographies, the company remains well positioned for sustained momentum and long-term leadership in neuromodulation and neurosurgical innovation.
BSX Stock Price Performance
Shares of Boston Scientific have lost 45.2% over the past year compared with the industry’s decline of 29%. The S&P 500 composite has grown 35.4% in the same period.
Image Source: Zacks Investment Research
Boston Scientific’s Valuation
From a valuation standpoint, BSX trades at a forward 12-month price-to-earnings ratio (P/E) of 3.76X, above the industry median of 3.09X.
Image Source: Zacks Investment Research
BSX Stock Consensus Estimate Trend
The Zacks Consensus Estimate for BSX’s earnings has moved south 2% over the past 30 days.
Image Source: Zacks Investment Research
BSX stock currently has a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power .
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
Medtronic PLC (MDT): Free Stock Analysis Report
NeuroPace, Inc. (NPCE): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).